SAN DIEGO--Privately held biopharmaceutical company Immusol announced its first genomics-based research collaboration with Pfizer to validate new therapeutic targets in the Pfizer drug discovery pipeline. A 1995 collaboration between the two firms to develop a gene therapy for the treatment of HIV will not be renewed, Immusol also announced. Instead, Immusol will continue to develop the HIV therapy in collaboration with Flossie Wong-Staal's laboratory at the University of California San Diego.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.